Natixis’s Ultragenyx Pharmaceutical RARE Stock Holding History

Natixis’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71M	Buy	+81,754	New	+$1.84M	0.01%	599
2024 Q4	–	Sell	-15,671	Closed	-$871K	–	1165
2024 Q3	$871K	Buy	+15,671	New	+$798K	﹤0.01%	549
2023 Q4	–	Sell	-33,100	Closed	-$1.18M	–	1151
2023 Q3	$1.18M	Sell	33,100 -31,600	-49%	-$1.25M	0.01%	479
2023 Q2	$2.98M	Buy	+64,700	New	+$3M	0.02%	364
2022 Q1	–	Sell	-15,863	Closed	-$1.33M	–	1295
2021 Q4	$1.33M	Sell	15,863 -20,143	-56%	-$1.64M	﹤0.01%	868
2021 Q3	$3.25M	Buy	+36,006	New	+$3.25M	0.01%	638
2021 Q2	–	Sell	-2,618	Closed	-$298K	–	945
2021 Q1	$298K	Sell	2,618 -162	-6%	-$22.1K	﹤0.01%	1000
2020 Q4	$385K	Buy	+2,780	New	+$330K	﹤0.01%	929

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Natixis's RARE Position: Q1 2026 in Review

Natixis opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 81,754 shares worth $1.71M. The stake represents 0.01% of the portfolio and ranks #599 among its holdings. This is a return to the name: Natixis previously reported a position in RARE as recently as Q3 2024.

Natixis first reported a position in RARE in Q4 2020 and has held it in 8 quarters since. The position peaked at $3.25M in Q3 2021. 297 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Natixis held 81,754 shares of Ultragenyx Pharmaceutical worth $1.71M as of Q1 2026.
Ultragenyx Pharmaceutical was a new Natixis position in Q1 2026.
Ultragenyx Pharmaceutical made up 0.01% of Natixis's portfolio in Q1 2026, its #599 holding.
Natixis first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 8 quarters since.
Natixis's Ultragenyx Pharmaceutical position peaked at $3.25M in Q3 2021.
297 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.